Boots Co., London, said U.S. and British clinical trials of a new drug showed it was less successful than expected in treating congestive heart failure.
The British pharmaceuticals and retailing concern added that ``the analysis of all the data isn't due to be completed for some weeks'' and that no decision has been made on the drug's future.
In a brief statement, however, Boots said a full evaluation of the results, which were particularly disappointing in the U.S. trials, could lead Boots to ``decide not to proceed with the Manoplax program in certain countries.'' It added, ``Complete cancellation is also a possibility.
